Dashboard
Manage Tickers

CNTX Context Therapeutics Inc.

Nasdaq contexttherapeutics.com


$ 1.21 $ -0.06 (-4.72 %)    

Wednesday, 22-Oct-2025 15:50:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.58 $ -5.89 (-0.96 %)
DIA $ 465.37 $ -3.44 (-0.73 %)
SPY $ 667.84 $ -3.49 (-0.52 %)
TLT $ 92.17 $ 0.06 (0.07 %)
GLD $ 376.97 $ 0.04 (0.01 %)
$ 1.21
$ 1.27
$ 1.21 x 64
$ 1.31 x 31
$ 1.19 - $ 1.31
$ 0.49 - $ 2.59
209,111
na
108.54M
$ 1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 12-02-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
10/16/2025 12:40:50

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

context-therapeutics-to-present-cancer-immunotherapy-data-at-sitc-2025
Context Therapeutics To Present Cancer Imm...
10/06/2025 11:38:40

Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical compan...

this-synopsys-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday
This Synopsys Analyst Begins Coverage On A...
10/02/2025 18:26:09

cantor-fitzgerald-initiates-coverage-on-context-therapeutics-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On Co...
10/02/2025 12:40:08

Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.

guggenheim-initiates-coverage-on-context-therapeutics-with-buy-rating-announces-price-target-of-5
Guggenheim Initiates Coverage On Context T...
09/18/2025 13:02:36

Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price ...

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
08/07/2025 11:39:00

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

hc-wainwright--co-maintains-buy-on-context-therapeutics-lowers-price-target-to-4
HC Wainwright & Co. Maintains Buy on Conte...
08/07/2025 10:57:38

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price ta...

context-therapeutics-q2-eps-009-misses-006-estimate-cash-and-cash-equivalents-were-835m-expected-to-be-sufficient-to-fund-its-operations-into-2027
Context Therapeutics Q2 EPS $(0.09) Misses...
08/06/2025 20:59:24

piper-sandler-reiterates-overweight-on-context-therapeutics-lowers-price-target-to-4
Piper Sandler Reiterates Overweight on Con...
06/26/2025 16:40:34

Piper Sandler analyst Biren Amin reiterates Context Therapeutics (NASDAQ:CNTX) with a Overweight and lowers the price target...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
06/05/2025 12:08:31

context-therapeutics-is-presenting-a-trial-in-progress-poster-for-the-phase-1-trial-of-ctim-76-in-ovarian-endometrial-and-testicular-cancers-at-the-2025-american-society-of-clinical-oncology-annual-meeting-expect-to-share-initial-data-in-the-first-half-of-2026
Context Therapeutics Is Presenting A Trial...
06/02/2025 11:33:53

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
05/08/2025 11:30:13

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

context-therapeutics-q1-eps-005-beats-009-estimate
Context Therapeutics Q1 EPS $(0.05) Beats ...
05/07/2025 21:27:07

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of ...

context-therapeutics-presents-new-preclinical-data-for-solid-tumor-therapy-at-major-cancer-conference
Context Therapeutics Presents New Preclini...
04/30/2025 11:37:06

Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company ad...

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
04/29/2025 11:30:42

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

william-blair-initiates-coverage-on-context-therapeutics-with-outperform-rating
William Blair Initiates Coverage On Contex...
04/21/2025 15:25:52

William Blair analyst Matt Phipps initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Outperform rating.

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
04/09/2025 12:29:32

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

context-therapeutics-announced-that-the-first-patient-has-been-dosed-in-the-phase-1-clinical-trial-of-ct-95-a-mesothelin-msln-x-cd3t-cell-engaging-tce-bispecific-antibody-designed-to-target-mesothelin-expressing-cancers
Context Therapeutics Announced That The Fi...
04/09/2025 11:32:15

hc-wainwright--co-reiterates-buy-on-context-therapeutics-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cont...
03/21/2025 11:39:00

HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price...

d-boral-capital-maintains-buy-on-context-therapeutics-maintains-9-price-target
D. Boral Capital Maintains Buy on Context ...
03/21/2025 11:10:12

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION